Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | POLD1 | P28340 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786791 | 0.87 | POLB (0.61) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL21787188 | 0.86 | TK1 (0.49) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL19662702 | 0.83 | TK1 (0.66) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL21787100 | 0.82 | TK1 (0.52) | TK1 | |
| SCHEMBL21787146 | 0.81 | POLB (0.52) | POLB | |
| SCHEMBL24913490 | 0.81 | POLB (0.62) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL21787053 | 0.81 | POLB (0.47) | POLBPOLA1 | |
| SCHEMBL23734160 | 0.80 | POLB (0.63) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL19663297 | 0.80 | POLB (0.63) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL23734161 | 0.80 | POLB (0.63) | TK1POLBPOLA1POLD1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | TK1 254/4885POLB 12/4885POLA1 126/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | TK1 244/4885POLB 11/4885POLA1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.